Europe's Agrifood Biotech Lead Is Slipping—Here's Why

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. World-class research institutes, established seed breeders, a food production ecosystem that runs like clockwork. On paper, it's the complete package. But a new report from Invest-NL, the Dutch national investment institution, suggests that reputation might be running on borrowed time. The report, called Deep Dive Agrifood Biotech, paints a picture of a country that's brilliant at starting things—and less brilliant at finishing them. ### The Startup-to-Scale-up Gap Here's the number that jumped out at me: the Netherlands accounts for 3.3% of BioTech startups worldwide, but only 1.3% of scale-ups. That's a gap you can't ignore. It means the country keeps planting seeds but struggles to grow them into trees. The data comes from TNO, the Netherlands Organisation for Applied Scientific Research, and it points to a pattern that shows up across the agrifood sector. Innovation isn't the problem. Commercialization is. Invest-NL identifies three recurring weak spots: - Too few promising technologies turn into scalable ventures - Regulatory and validation processes slow down market entry - Financing gaps prevent companies from reaching industrial production ### What's at Stake This isn't just about national pride. The report estimates that fixing these barriers could unlock roughly $18.4 billion in additional annual revenue by 2040. In a favorable scenario, Dutch agrifood biotech revenues could hit about $27 billion annually. Under current conditions? Just $8.6 to $9.7 billion. That's a lot of money left on the table. ### Ten Years to Say Yes Perhaps the most frustrating obstacle involves biological crop protection—the alternatives to conventional chemical pesticides that Dutch companies are developing. Getting European regulatory approval for a new biological product can take eight to ten years. Eight to ten years. No wonder some companies pack up and launch in Brazil or the United States instead, where commercialization moves faster. Europe risks losing ground in a market that could expand seven- to tenfold by 2040. Food biotechnology faces similar headaches. Novel ingredient approvals take one to three years longer in Europe than in the U.S., and building a first commercial production facility can require tens or even hundreds of millions of dollars. > "Faster approvals shouldn't come at the expense of safety," the report notes. Instead, it calls for earlier guidance, more predictable assessments, and real-world validation opportunities. ### The Real Lesson Here's the thing the report makes clear: the Netherlands doesn't need to manufacture everything at home. What it needs is to hold onto the valuable stuff—the knowledge, the intellectual property, the companies, the specialized skills—while leaning on European production networks where it makes sense. For anyone watching European startup incorporation and agrifood innovation, this is a wake-up call. Scientific excellence alone doesn't build globally competitive businesses. You need regulation that keeps pace, financing that scales, and a system that turns research into revenue before someone else does it first.